Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant Disease
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Taken together, genes with evidence of RNA splicing and transcript alternations in endometriosis may serve as potential biomarkers and therapeutic targets, especially considering the promising translational value of RNA splicing in clinical applications.53,54”
From Regulation of RNA splicing in endometrial tissue and its association with endometriosis (2025) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hindorff, L. A., Sethupathy, P., Junkins, H. A., Ramos, E. M., Mehta, J. P., Collins, F. S., & Manolio, T. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903103106 · Cited by 4,013
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Spliceosome Structure and Function
Will, C. L., & Luhrmann, R. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003707 · Cited by 1,829
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222
Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D. (2017) · Science · doi:10.1126/science.aal3755 · Cited by 762
RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing
Guo, W., Schafer, S., Greaser, M. L., Radke, M. H., Liss, M., Govindarajan, T., Maatz, H., Schulz, H., Li, S., Parrish, A. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2693 · Cited by 589
SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
Naryshkin, N. A., Weetall, M., Dakka, A., Narasimhan, J., Zhao, X., Feng, Z., Ling, K. K. Y., Karp, G. M., Qi, H., Woll, M. G., et al. (2014) · Science · doi:10.1126/science.1250127 · Cited by 524
SMN2 splice modulators enhance U1–pre-mRNA association and rescue SMA mice
Palacino, J., Swalley, S. E., Song, C., Cheung, A. K., Shu, L., Zhang, X., Van Hoosear, M., Shin, Y., Chin, D. N., Keller, C. G., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1837 · Cited by 432
Selective degradation of splicing factor CAPERα by anticancer sulfonamides
Uehara, T., Minoshima, Y., Sagane, K., Sugi, N. H., Mitsuhashi, K. O., Yamamoto, N., Kamiyama, H., Takahashi, K., Kotake, Y., Uesugi, M., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2363 · Cited by 396
Antitumorigenic potential of STAT3 alternative splicing modulation
Zammarchi, F., de Stanchina, E., Bournazou, E., Supakorndej, T., Martires, K., Riedel, E., Corben, A. D., Bromberg, J. F., & Cartegni, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108482108 · Cited by 176
Genome-wide Analysis of Alternative Pre-mRNA Splicing
Ben-Dov, C., Hartmann, B., Lundgren, J., & Valcárcel, J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r700033200 · Cited by 151
SnapShot: The Splicing Regulatory Machinery
Gabut, M., Chaudhry, S., & Blencowe, B. J. (2008) · Cell · doi:10.1016/j.cell.2008.03.010 · Cited by 66
van Amstel, J. K. P., Bergman, A. J. I. W., van Beurden, E. A. C. M., Roijers, J. F. M., Peelen, T., van den Berg, I. E. T., Poll-The, B. T., Kvittingen, E. A., & Berger, R. (1996) · Human Genetics · doi:10.1007/bf00218833 · Cited by 60
Research works printed but not linked: 156
- Doolittle, 1978, Genes in pieces: were they ever together?, Nature, 272, 581, 10.1038/272581a0 · DOI · Paper page
- Matlin, 2005, Understanding alternative splicing: towards a cellular code, Nat. Rev. Mol. Cell Biol., 6, 386, 10.1038/nrm1645 · DOI · Paper page
- Blencowe, 2006, Alternative splicing: new insights from global analyses, Cell, 126, 37, 10.1016/j.cell.2006.06.023 · DOI · Paper page
- Wang, 2008, Splicing regulation: from a parts list of regulatory elements to an integrated splicing code, RNA, 14, 802, 10.1261/rna.876308 · DOI · Paper page
- Schaal, 1999, Multiple distinct splicing enhancers in the protein-coding sequences of a constitutively spliced pre-mRNA, Mol. Cell. Biol., 19, 261, 10.1128/MCB.19.1.261 · DOI · Paper page
- Fairbrother, 2002, Predictive identification of exonic splicing enhancers in human genes, Science, 297, 1007, 10.1126/science.1073774 · DOI · Paper page
- Jobbins, 2018, The mechanisms of a mammalian splicing enhancer, Nucleic Acids Res., 46, 2145, 10.1093/nar/gky056 · DOI
- Pozzoli, 2005, Silencers regulate both constitutive and alternative splicing events in mammals, Cell. Mol. Life Sci., 62, 1579, 10.1007/s00018-005-5030-6 · DOI
- Wang, 2006, General and specific functions of exonic splicing silencers in splicing control, Mol. Cell, 23, 61, 10.1016/j.molcel.2006.05.018 · DOI · Paper page
- Ladd, 2002, Finding signals that regulate alternative splicing in the post-genomic era, Genome Biol., 3, 10.1186/gb-2002-3-11-reviews0008 · DOI
- Scamborova, 2004, An intronic enhancer regulates splicing of the twintron of Drosophila melanogaster prospero pre-mRNA by two different spliceosomes, Mol. Cell. Biol., 24, 1855, 10.1128/MCB.24.5.1855-1869.2004 · DOI
- Wang, 2012, Intronic splicing enhancers, cognate splicing factors and context-dependent regulation rules, Nat. Struct. Mol. Biol., 19, 1044, 10.1038/nsmb.2377 · DOI · Paper page
- Zheng, 2004, Regulation of alternative RNA splicing by exon definition and exon sequences in viral and mammalian gene expression, J. Biomed. Sci., 11, 278, 10.1007/BF02254432 · DOI · Paper page
- Busch, 2012, Evolution of SR protein and hnRNP splicing regulatory factors, Wiley Interdiscip. Rev. RNA, 3, 1, 10.1002/wrna.100 · DOI · Paper page
- Graveley, 2000, Sorting out the complexity of SR protein functions, RNA, 6, 1197, 10.1017/S1355838200000960 · DOI · Paper page
- Shepard, 2009, The SR protein family, Genome Biol., 10, 242, 10.1186/gb-2009-10-10-242 · DOI · Paper page
- Scotti, 2016, RNA mis-splicing in disease, Nat. Rev. Genet., 17, 19, 10.1038/nrg.2015.3 · DOI · Paper page
- Verma, 2018, Minor spliceosome and disease, Semin. Cell Dev. Biol., 79, 103, 10.1016/j.semcdb.2017.09.036 · DOI
- Krawczak, 2007, Single base-pair substitutions in exon–intron junctions of human genes: nature, distribution, and consequences for mRNA splicing, Hum. Mutat., 28, 150, 10.1002/humu.20400 · DOI · Paper page
- Lim, 2011, Using positional distribution to identify splicing elements and predict pre-mRNA processing defects in human genes, Proc. Natl. Acad. Sci. U. S. A., 108, 11093, 10.1073/pnas.1101135108 · DOI · Paper page
- Mueller, 2015, The silent sway of splicing by synonymous substitutions, J. Biol. Chem., 290, 27700, 10.1074/jbc.M115.684035 · DOI
- Lee, 2016, Therapeutic targeting of splicing in cancer, Nat. Med., 22, 976, 10.1038/nm.4165 · DOI · Paper page
- Baumgartner, 2018, Minor spliceosome inactivation causes microcephaly, owing to cell cycle defects and death of self-amplifying radial glial cells, Development, 145, 10.1242/dev.166322 · DOI · Paper page
- Sune-Pou, 2020, Innovative therapeutic and delivery approaches using nanotechnology to correct splicing defects underlying disease, Front. Genet., 11, 731, 10.3389/fgene.2020.00731 · DOI
- Havens, 2016, Splice-switching antisense oligonucleotides as therapeutic drugs, Nucleic Acids Res., 44, 6549, 10.1093/nar/gkw533 · DOI · Paper page
- Rigo, 2014, Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects, Adv. Exp. Med. Biol., 825, 303, 10.1007/978-1-4939-1221-6_9 · DOI
- Bauman, 2009, Therapeutic potential of splice-switching oligonucleotides, Oligonucleotides, 19, 1, 10.1089/oli.2008.0161 · DOI · Paper page
- Du, 2009, Progress toward therapy with antisense-mediated splicing modulation, Curr. Opin. Mol. Ther., 11, 116
- Peacey, 2012, Targeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicing, Nucleic Acids Res., 40, 9836, 10.1093/nar/gks710 · DOI
- Rigo, 2012, Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing, Nat. Chem. Biol., 8, 555, 10.1038/nchembio.939 · DOI · Paper page
- Villemaire, 2003, Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides, J. Biol. Chem., 278, 50031, 10.1074/jbc.M308897200 · DOI
- Bauman, 2011, Modulation of RNA splicing as a potential treatment for cancer, Bioeng. Bugs, 2, 125, 10.4161/bbug.2.3.15165 · DOI
- Bauman, 2010, Anti-tumor activity of splice-switching oligonucleotides, Nucleic Acids Res., 38, 8348, 10.1093/nar/gkq731 · DOI
- Stepniak-Konieczna, 2020, AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for myotonic dystrophy type 1, Nucleic Acids Res., 48, 2531, 10.1093/nar/gkaa007 · DOI
- Lefave, 2011, Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas, EMBO J., 30, 4084, 10.1038/emboj.2011.259 · DOI
- Ward, 2014, Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides, Nucleic Acids Res., 42, 5871, 10.1093/nar/gku184 · DOI · Paper page
- Skordis, 2003, Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts, Proc. Natl. Acad. Sci. U. S. A., 100, 4114, 10.1073/pnas.0633863100 · DOI · Paper page
- Becker, 1962, Two families of benign sex-linked recessive muscular dystrophy, Rev. Can. Biol., 21, 551
- Becker, 1955, A new x-chromosomal muscular dystrophy, Arch. Psychiatr. Nervenkr. Z. Gesamte Neurol. Psychiatr., 193, 427, 10.1007/BF00343141 · DOI · Paper page
- Muntoni, 2003, Dystrophin and mutations: one gene, several proteins, multiple phenotypes, Lancet Neurol., 2, 731, 10.1016/S1474-4422(03)00585-4 · DOI · Paper page
- Baccon, 2002, Identification and characterization of Gemin7, a novel component of the survival of motor neuron complex, J. Biol. Chem., 277, 31957, 10.1074/jbc.M203478200 · DOI
- Fischer, 1997, The SMN–SIP1 complex has an essential role in spliceosomal snRNP biogenesis, Cell, 90, 1023, 10.1016/S0092-8674(00)80368-2 · DOI · Paper page
- Meister, 2001, A multiprotein complex mediates the ATP-dependent assembly of spliceosomal U snRNPs, Nat. Cell Biol., 3, 945, 10.1038/ncb1101-945 · DOI · Paper page
- Kamdar, 2016, Dystrophin-deficient cardiomyopathy, J. Am. Coll. Cardiol., 67, 2533, 10.1016/j.jacc.2016.02.081 · DOI · Paper page
- Mendell, 2013, Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy, Muscle Nerve, 48, 21, 10.1002/mus.23810 · DOI · Paper page
- Mah, 2014, A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy, Neuromuscul. Disord., 24, 482, 10.1016/j.nmd.2014.03.008 · DOI · Paper page
- Arahata, 1991, Preservation of the C-terminus of dystrophin molecule in the skeletal muscle from Becker muscular dystrophy, J. Neurol. Sci., 101, 148, 10.1016/0022-510X(91)90039-A · DOI
- Takeshima, 1995, Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe, J. Clin. Invest., 95, 515, 10.1172/JCI117693 · DOI
- Dunckley, 1998, Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides, Hum. Mol. Genet., 7, 1083, 10.1093/hmg/7.7.1083 · DOI · Paper page
- van Deutekom, 2001, Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells, Hum. Mol. Genet., 10, 1547, 10.1093/hmg/10.15.1547 · DOI · Paper page
- Alter, 2006, Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology, Nat. Med., 12, 175, 10.1038/nm1345 · DOI · Paper page
- Heemskerk, 2010, Preclinical PK and PD studies on 2′-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model, Mol. Ther., 18, 1210, 10.1038/mt.2010.72 · DOI · Paper page
- Tanganyika-de Winter, 2012, Long-term exon skipping studies With 2′-O-methyl phosphorothioate antisense oligonucleotides in dystrophic mouse models, Mol. Ther. Nucleic Acids, 1, 10.1038/mtna.2012.38 · DOI
- Yokota, 2009, Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs, Ann. Neurol., 65, 667, 10.1002/ana.21627 · DOI · Paper page
- Lim, 2017, Eteplirsen in the treatment of Duchenne muscular dystrophy, Drug Des. Devel. Ther., 11, 533, 10.2147/DDDT.S97635 · DOI · Paper page
- Wurster, 2018, Antisense oligonucleotides in neurological disorders, Ther. Adv. Neurol. Disord., 11, 10.1177/1756286418776932 · DOI
- Kole, 2015, Exon skipping therapy for Duchenne muscular dystrophy, Adv. Drug Deliv. Rev., 87, 104, 10.1016/j.addr.2015.05.008 · DOI · Paper page
- Komaki, 2018, Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy, Sci. Transl. Med., 10, 10.1126/scitranslmed.aan0713 · DOI
- Heo, 2020, Golodirsen: first approval, Drugs, 80, 329, 10.1007/s40265-020-01267-2 · DOI · Paper page
- Kolb, 2011, Spinal muscular atrophy: a timely review, Arch. Neurol., 68, 979, 10.1001/archneurol.2011.74 · DOI · Paper page
- Lefebvre, 1995, Identification and characterization of a spinal muscular atrophy-determining gene, Cell, 80, 155, 10.1016/0092-8674(95)90460-3 · DOI · Paper page
- Yong, 2004, Why do cells need an assembly machine for RNA–protein complexes?, Trends Cell Biol., 14, 226, 10.1016/j.tcb.2004.03.010 · DOI · Paper page
- Mailman, 2002, Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2, Genet. Med., 4, 20, 10.1097/00125817-200201000-00004 · DOI · Paper page
- Prior, 2004, Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2, Am. J. Med. Genet. A, 130A, 307, 10.1002/ajmg.a.30251 · DOI · Paper page
- Lim, 2001, Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3’ splice site pairing, J. Biol. Chem., 276, 45476, 10.1074/jbc.M107632200 · DOI · Paper page
- Miyajima, 2002, Identification of a cis-acting element for the regulation of SMN exon 7 splicing, J. Biol. Chem., 277, 23271, 10.1074/jbc.M200851200 · DOI
- Singh, 2006, Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron, Mol. Cell. Biol., 26, 1333, 10.1128/MCB.26.4.1333-1346.2006 · DOI · Paper page
- Baughan, 2009, Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy, Hum. Mol. Genet., 18, 1600, 10.1093/hmg/ddp076 · DOI · Paper page
- Le, 2005, SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN, Hum. Mol. Genet., 14, 845, 10.1093/hmg/ddi078 · DOI · Paper page
- Hua, 2008, Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice, Am. J. Hum. Genet., 82, 834, 10.1016/j.ajhg.2008.01.014 · DOI · Paper page
- Hua, 2010, Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model, Genes Dev., 24, 1634, 10.1101/gad.1941310 · DOI · Paper page
- Passini, 2011, Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy, Sci. Transl. Med., 3, 10.1126/scitranslmed.3001777 · DOI · Paper page
- Singh, 2017, How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy, Gene Ther., 24, 520, 10.1038/gt.2017.34 · DOI · Paper page
- Feng, 2016, Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset, Hum. Mol. Genet., 25, 964, 10.1093/hmg/ddv629 · DOI
- Ratni, 2018, Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA), J. Med. Chem., 61, 6501, 10.1021/acs.jmedchem.8b00741 · DOI · Paper page
- Sivaramakrishnan, 2017, Binding to SMN2 pre-mRNA–protein complex elicits specificity for small molecule splicing modifiers, Nat. Commun., 8, 1476, 10.1038/s41467-017-01559-4 · DOI · Paper page
- Sturm, 2019, A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier, Br. J. Clin. Pharmacol., 85, 181, 10.1111/bcp.13786 · DOI
- Ando, 2020, Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy, Sci. Rep., 10, 17472, 10.1038/s41598-020-74346-9 · DOI
- Goodall, 2021, RNA in cancer, Nat. Rev. Cancer, 21, 22, 10.1038/s41568-020-00306-0 · DOI · Paper page
- Graubert, 2011, Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes, Nat. Genet., 44, 53, 10.1038/ng.1031 · DOI · Paper page
- Quesada, 2011, Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia, Nat. Genet., 44, 47, 10.1038/ng.1032 · DOI · Paper page
- Rahman, 2020, SnapShot: splicing alterations in cancer, Cell, 180, 208, 10.1016/j.cell.2019.12.011 · DOI
- Wang, 2011, SF3B1 and other novel cancer genes in chronic lymphocytic leukemia, N. Engl. J. Med., 365, 2497, 10.1056/NEJMoa1109016 · DOI · Paper page
- Cazzola, 2020, Myelodysplastic syndromes, N. Engl. J. Med., 383, 1358, 10.1056/NEJMra1904794 · DOI · Paper page
- Harbour, 2013, Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma, Nat. Genet., 45, 133, 10.1038/ng.2523 · DOI · Paper page
- Martin, 2013, Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3, Nat. Genet., 45, 933, 10.1038/ng.2674 · DOI · Paper page
- Suzuki, 2019, Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma, Nature, 574, 707, 10.1038/s41586-019-1650-0 · DOI · Paper page
- Shuai, 2019, The U1 spliceosomal RNA is recurrently mutated in multiple cancers, Nature, 574, 712, 10.1038/s41586-019-1651-z · DOI · Paper page
- Chen, 2018, The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations, Mol. Cell, 69, 412, 10.1016/j.molcel.2017.12.029 · DOI · Paper page
- Inoue, 2019, Spliceosomal disruption of the non-canonical BAF complex in cancer, Nature, 574, 432, 10.1038/s41586-019-1646-9 · DOI · Paper page
- Agrawal, 2018, Targeting splicing abnormalities in cancer, Curr. Opin. Genet. Dev., 48, 67, 10.1016/j.gde.2017.10.010 · DOI
- Eskens, 2013, Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors, Clin. Cancer Res., 19, 6296, 10.1158/1078-0432.CCR-13-0485 · DOI · Paper page
- Hong, 2014, A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors, Investig. New Drugs, 32, 436, 10.1007/s10637-013-0046-5 · DOI · Paper page
- Crews, 2016, RNA splicing modulation selectively impairs leukemia stem cell maintenance in secondary human AML, Cell Stem Cell, 19, 599, 10.1016/j.stem.2016.08.003 · DOI · Paper page
- Seiler, 2018, H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers, Nat. Med., 24, 497, 10.1038/nm.4493 · DOI · Paper page
- Fong, 2019, Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation, Cancer Cell, 36, 194, 10.1016/j.ccell.2019.07.003 · DOI · Paper page
- Radzisheuskaya, 2019, PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia, Nat. Struct. Mol. Biol., 26, 999, 10.1038/s41594-019-0313-z · DOI · Paper page
- Will, 2001, Spliceosomal UsnRNP biogenesis, structure and function, Curr. Opin. Cell Biol., 13, 290, 10.1016/S0955-0674(00)00211-8 · DOI · Paper page
- Turunen, 2013, The significant other: splicing by the minor spliceosome, Wiley Interdiscip. Rev. RNA, 4, 61, 10.1002/wrna.1141 · DOI · Paper page
- Daubner, 2012, A syn-anti conformational difference allows SRSF2 to recognize guanines and cytosines equally well, EMBO J., 31, 162, 10.1038/emboj.2011.367 · DOI
- Shamoo, 1997, Crystal structure of the two RNA binding domains of human hnRNP A1 at 1.75 Å resolution, Nat. Struct. Biol., 4, 215, 10.1038/nsb0397-215 · DOI
- Dietrich, 1997, Terminal intron dinucleotide sequences do not distinguish between U2- and U12-dependent introns, Mol. Cell, 1, 151, 10.1016/S1097-2765(00)80016-7 · DOI
- Argente, 2014, Defective minor spliceosome mRNA processing results in isolated familial growth hormone deficiency, Embo Mol. Med., 6, 299, 10.1002/emmm.201303573 · DOI · Paper page
- Edery, 2011, Association of TALS developmental disorder with defect in minor splicing component U4atac snRNA, Science, 332, 240, 10.1126/science.1202205 · DOI · Paper page
- He, 2011, Mutations in U4atac snRNA, a component of the minor spliceosome, in the developmental disorder MOPD I, Science, 332, 238, 10.1126/science.1200587 · DOI · Paper page
- Merico, 2015, Compound heterozygous mutations in the noncoding RNU4ATAC cause Roifman syndrome by disrupting minor intron splicing, Nat. Commun., 6, 8718, 10.1038/ncomms9718 · DOI · Paper page
- Cologne, 2019, New insights into minor splicing – a transcriptomic analysis of cells derived from TALS patients, RNA, 25, 1130, 10.1261/rna.071423.119 · DOI
- Farach, 2018, The expanding phenotype of RNU4ATAC pathogenic variants to Lowry Wood syndrome, Am. J. Med. Genet. A, 176, 465, 10.1002/ajmg.a.38581 · DOI
- Hastings, 2005, An LKB1 AT–AC intron mutation causes Peutz–Jeghers syndrome via splicing at noncanonical cryptic splice sites, Nat. Struct. Mol. Biol., 12, 54, 10.1038/nsmb873 · DOI
- Shaw, 2003, Identification of three novel SEDL mutations, including mutation in the rare, non-canonical splice site of exon 4, Clin. Genet., 64, 235, 10.1034/j.1399-0004.2003.00132.x · DOI
- Ishihara, 2013, Decreased number of gemini of coiled bodies and U12 snRNA level in amyotrophic lateral sclerosis, Hum. Mol. Genet., 22, 4136, 10.1093/hmg/ddt262 · DOI
- Reber, 2016, Minor intron splicing is regulated by FUS and affected by ALS-associated FUS mutants, EMBO J., 35, 1504, 10.15252/embj.201593791 · DOI
- Sun, 2015, ALS-causative mutations in FUS/TLS confer gain and loss of function by altered association with SMN and U1-snRNP, Nat. Commun., 6, 6171, 10.1038/ncomms7171 · DOI · Paper page
- Li, 2014, SMN control of RNP assembly: from post-transcriptional gene regulation to motor neuron disease, Semin. Cell Dev. Biol., 32, 22, 10.1016/j.semcdb.2014.04.026 · DOI · Paper page
- Zhang, 2008, SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing, Cell, 133, 585, 10.1016/j.cell.2008.03.031 · DOI · Paper page
- Disset, 2006, An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements, Hum. Mol. Genet., 15, 999, 10.1093/hmg/ddl015 · DOI
- Taniguchi-Ikeda, 2011, Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy, Nature, 478, 127, 10.1038/nature10456 · DOI · Paper page
- Samaranch, 2010, PINK1-linked parkinsonism is associated with Lewy body pathology, Brain, 133, 1128, 10.1093/brain/awq051 · DOI · Paper page
- Iovino, 2014, The novel MAPT mutation K298E: mechanisms of mutant tau toxicity, brain pathology and tau expression in induced fibroblast-derived neurons, Acta Neuropathol., 127, 283, 10.1007/s00401-013-1219-1 · DOI · Paper page
- Norcliffe-Kaufmann, 2012, Familial dysautonomia (Riley–Day syndrome): when baroreceptor feedback fails, Auton. Neurosci., 172, 26, 10.1016/j.autneu.2012.10.012 · DOI
- Otomo, 2005, Electrophysiological and histopathological characteristics of progressive atrioventricular block accompanied by familial dilated cardiomyopathy caused by a novel mutation of lamin A/C gene, J. Cardiovasc. Electrophysiol., 16, 137, 10.1046/j.1540-8167.2004.40096.x · DOI · Paper page
- Eriksson, 2003, Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome, Nature, 423, 293, 10.1038/nature01629 · DOI · Paper page
- Muchir, 2000, Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B), Hum. Mol. Genet., 9, 1453, 10.1093/hmg/9.9.1453 · DOI · Paper page
- Morel, 2006, A LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy type 2, J. Clin. Endocrinol. Metab., 91, 2689, 10.1210/jc.2005-2746 · DOI · Paper page
- Zhu, 2007, A common polymorphism decreases low-density lipoprotein receptor exon 12 splicing efficiency and associates with increased cholesterol, Hum. Mol. Genet., 16, 1765, 10.1093/hmg/ddm124 · DOI · Paper page
- Ho, 2015, LDLR gene synonymous mutation c.1813C>T results in mRNA splicing variation in a kindred with familial hypercholesterolaemia, Ann. Clin. Biochem., 52, 680, 10.1177/0004563215572702 · DOI
- Tanackovic, 2011, PRPF mutations are associated with generalized defects in spliceosome formation and pre-mRNA splicing in patients with retinitis pigmentosa, Hum. Mol. Genet., 20, 2116, 10.1093/hmg/ddr094 · DOI · Paper page
- Vieira, 2014, A defect in the RNA-processing protein HNRPDL causes limb-girdle muscular dystrophy 1G (LGMD1G), Hum. Mol. Genet., 23, 4103, 10.1093/hmg/ddu127 · DOI · Paper page
- Bartoletti-Stella, 2017, Messenger RNA processing is altered in autosomal dominant leukodystrophy, Hum. Mol. Genet., 26, 3868, 10.1093/hmg/ddx225 · DOI
- Nielsen, 2007, Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer, Am. J. Hum. Genet., 80, 416, 10.1086/511992 · DOI
- Thornton, 2014, Myotonic dystrophy, Neurol. Clin., 32, 705, 10.1016/j.ncl.2014.04.011 · DOI · Paper page
- Aznarez, 2003, Characterization of disease-associated mutations affecting an exonic splicing enhancer and two cryptic splice sites in exon 13 of the cystic fibrosis transmembrane conductance regulator gene, Hum. Mol. Genet., 12, 2031, 10.1093/hmg/ddg215 · DOI
- Kiritsi, 2011, Molecular mechanisms of phenotypic variability in junctional epidermolysis bullosa, J. Med. Genet., 48, 450, 10.1136/jmg.2010.086751 · DOI
- Camacho Vanegas, 2001, Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI, Proc. Natl. Acad. Sci. U. S. A., 98, 7516, 10.1073/pnas.121027598 · DOI · Paper page
- Barbaux, 1997, Donor splice-site mutations in WT1 are responsible for Frasier syndrome, Nat. Genet., 17, 467, 10.1038/ng1297-467 · DOI · Paper page
- Busslinger, 1981, Beta+ thalassemia: aberrant splicing results from a single point mutation in an intron, Cell, 27, 289, 10.1016/0092-8674(81)90412-8 · DOI · Paper page
- Treisman, 1983, Specific transcription and RNA splicing defects in five cloned beta-thalassaemia genes, Nature, 302, 591, 10.1038/302591a0 · DOI · Paper page
- Tumer, 2013, An overview and update of ATP7A mutations leading to Menkes disease and occipital horn syndrome, Hum. Mutat., 34, 417, 10.1002/humu.22266 · DOI
- Yanaizu, 2018, Small nuclear RNA-mediated modulation of splicing reveals a therapeutic strategy for a TREM2 mutation and its post-transcriptional regulation, Sci. Rep., 8, 6937, 10.1038/s41598-018-25204-2 · DOI
- van der Woerd, 2015, Analysis of aberrant pre-messenger RNA splicing resulting from mutations in ATP8B1 and efficient in vitro rescue by adapted U1 small nuclear RNA, Hepatology, 61, 1382, 10.1002/hep.27620 · DOI
- Coutinho, 2008, Molecular characterization of Portuguese patients with mucopolysaccharidosis IIIC: two novel mutations in the HGSNAT gene, Clin. Genet., 74, 194, 10.1111/j.1399-0004.2008.01040.x · doi:10.1111/j.1399-0004.2008.01040.x
- Sathasivam, 2013, Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease, Proc. Natl. Acad. Sci. U. S. A., 110, 2366, 10.1073/pnas.1221891110 · DOI · Paper page
- Chen, 1991, Splice junction mutations in factor IX gene resulting in severe hemophilia B, Nucleic Acids Res., 19, 1172, 10.1093/nar/19.5.1172 · doi:10.1093/nar/19.5.1172
- El-Maarri, 2005, Analysis of mRNA in hemophilia A patients with undetectable mutations reveals normal splicing in the factor VIII gene, J. Thromb. Haemost., 3, 332, 10.1111/j.1538-7836.2005.01140.x · DOI
- den Hollander, 2006, Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis, Am. J. Hum. Genet., 79, 556, 10.1086/507318 · DOI · Paper page
- Olsson, 2008, Myopathy with lactic acidosis is linked to chromosome 12q23.3-24.11 and caused by an intron mutation in the ISCU gene resulting in a splicing defect, Hum. Mol. Genet., 17, 1666, 10.1093/hmg/ddn057 · DOI · Paper page
- Mentrup, 2017, A homozygous intronic branch-point deletion in the ALPL gene causes infantile hypophosphatasia, Bone, 94, 75, 10.1016/j.bone.2016.10.022 · DOI
- Paron, 2020, Pre-mRNA splicing defects and RNA binding protein involvement in Niemann Pick type C disease, J. Biotechnol., 318, 20, 10.1016/j.jbiotec.2020.03.012 · DOI
- Bergsma, 2015, Identification and characterization of aberrant GAA pre-mRNA splicing in pompe disease using a generic approach, Hum. Mutat., 36, 57, 10.1002/humu.22705 · DOI
- Kishore, 2006, Regulation of alternative splicing by snoRNAs, Cold Spring Harb. Symp. Quant. Biol., 71, 329, 10.1101/sqb.2006.71.024 · DOI · Paper page
- Abuhatzira, 2005, Splicing mutation associated with Rett syndrome and an experimental approach for genetic diagnosis, Hum. Genet., 118, 91, 10.1007/s00439-005-0025-9 · doi:10.1007/s00439-005-0025-9
- Osenberg, 2018, Activity-dependent aberrations in gene expression and alternative splicing in a mouse model of Rett syndrome, Proc. Natl. Acad. Sci. U. S. A., 115, E5363, 10.1073/pnas.1722546115 · DOI
- Ahmed, 2008, Gene structure and mutant alleles of PCDH15: nonsyndromic deafness DFNB23 and type 1 Usher syndrome, Hum. Genet., 124, 215, 10.1007/s00439-008-0543-3 · DOI
- Bestas, 2015, Splice-correction strategies for treatment of X-linked agammaglobulinemia, Curr Allergy Asthma Rep, 15, 510, 10.1007/s11882-014-0510-0 · DOI
- Martin, 2012, The survival motor neuron protein forms soluble glycine zipper oligomers, Structure, 20, 1929, 10.1016/j.str.2012.08.024 · DOI
- Jagtap, 2020, Identification of phenothiazine derivatives as UHM-binding inhibitors of early spliceosome assembly, Nat. Commun., 11, 5621, 10.1038/s41467-020-19514-1 · DOI
Cited by
Bewersdorf, J. P., Stahl, M., Taylor, J., Mi, X., Chandhok, N. S., Watts, J., Derkach, A., Wysocki, M., Lu, S. X., Bourcier, J., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02050-4 · Cited by 62
“Targeting residual splicing function could therefore lead to synthetic lethality and constitute a potent therapeutic approach to splicing factor-mutant AML/MDS [5].”
BackgroundSelf-citationScreening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids
Wan, L., Kral, A. J., Voss, D., Schäfer, B., Sudheendran, K., Danielsen, M., Caruthers, M. H., & Krainer, A. R. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2023.0070 · Cited by 17
Regulation of RNA splicing in endometrial tissue and its association with endometriosis
Yang, F., Qi, T., McRae, A. F., Rogers, P. A. W., Montgomery, G. W., & Mortlock, S. (2025) · iScience · doi:10.1016/j.isci.2025.113207 · Cited by 4
Metadata
- Authors
- El Marabti, E., & Abdel-Wahab, O.
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 27
- Issue
- 7
- Pages
- 643-659
- ISSN
- 1471-4914
- Cited by
- 71
- References
- 13
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- National Institutes of Health
- NHLBI (R01 HL128239)
- NCI (R01 CA242020, R01 CA251138)
- Edward P. Evans Foundation
- Henry and Marilyn Taub Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.